Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience

• Published in: Translational psychiatry Vol. 14; no. 1; pp. 372 - 11
• Main Authors: Nicholas, Christopher R., Banks, Matthew I., Lennertz, Richard C., Wenthur, Cody J., Krause, Bryan M., Riedner, Brady A., Smith, Richard F., Hutson, Paul R., Sauder, Christina J., Dunne, John D., Roseman, Leor, Raison, Charles L.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.09.2024; Nature Publishing Group
• Subjects: 631/378; 631/378/1595; 631/378/1595/2167; Adult; Anesthesia; Behavioral Sciences; Benzodiazepines; Biological Psychology; Drug dosages; Female; Hallucinogens - administration & dosage; Hallucinogens - pharmacology; Health care; Humans; Male; Medicine; Medicine & Public Health; Memory; Memory - drug effects; Midazolam - administration & dosage; Midazolam - pharmacology; Neurosciences; Pharmacotherapy; Psilocybin - administration & dosage; Psilocybin - pharmacology; Psychedelic drugs; Psychiatry; Public health; Young Adult
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-024-03059-8

Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and improved well-being in healthy participants, but whether these therapeutic effects are immediate or are based on memories of the experience is unclear. To examine this, we co-administered psilocybin (25 mg) with the amnestic benzodiazepine midazolam in 8 healthy participants and assayed the subjective quality of, and memory for, the dosing-day experience. We identified a midazolam dose that allowed a conscious psychedelic experience to occur while partially impairing memory for the experience. Furthermore, midazolam dose and memory impairment tended to associate inversely with salience, insight, and well-being induced by psilocybin. These data suggest a role for memory in therapeutically relevant behavioral effects occasioned by psilocybin. Because midazolam blocks memory by blocking cortical neural plasticity, it may also be useful for evaluating the contribution of the pro-neuroplastic properties of psychedelics to their therapeutic activity.